BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 17892374)

  • 1. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.
    Recker RR; Delmas PD; Halse J; Reid IR; Boonen S; García-Hernandez PA; Supronik J; Lewiecki EM; Ochoa L; Miller P; Hu H; Mesenbrink P; Hartl F; Gasser J; Eriksen EF
    J Bone Miner Res; 2008 Jan; 23(1):6-16. PubMed ID: 17892374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project].
    Dalle Carbonare L; Bertoldo F; Lo Cascio V
    Reumatismo; 2009; 61(1):54-64. PubMed ID: 19370189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
    Reid IR; Brown JP; Burckhardt P; Horowitz Z; Richardson P; Trechsel U; Widmer A; Devogelaer JP; Kaufman JM; Jaeger P; Body JJ; Brandi ML; Broell J; Di Micco R; Genazzani AR; Felsenberg D; Happ J; Hooper MJ; Ittner J; Leb G; Mallmin H; Murray T; Ortolani S; Rubinacci A; Saaf M; Samsioe G; Verbruggen L; Meunier PJ
    N Engl J Med; 2002 Feb; 346(9):653-61. PubMed ID: 11870242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis.
    Dalle Carbonare L; Arlot ME; Chavassieux PM; Roux JP; Portero NR; Meunier PJ
    J Bone Miner Res; 2001 Jan; 16(1):97-103. PubMed ID: 11149495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84.
    Recker RR; Bare SP; Smith SY; Varela A; Miller MA; Morris SA; Fox J
    Bone; 2009 Jan; 44(1):113-9. PubMed ID: 18983947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid.
    Gamsjaeger S; Buchinger B; Zwettler E; Recker R; Black D; Gasser JA; Eriksen EF; Klaushofer K; Paschalis EP
    J Bone Miner Res; 2011 Jan; 26(1):12-8. PubMed ID: 20645415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography.
    Borah B; Dufresne TE; Chmielewski PA; Johnson TD; Chines A; Manhart MD
    Bone; 2004 Apr; 34(4):736-46. PubMed ID: 15050906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis.
    Delmas PD; Munoz F; Black DM; Cosman F; Boonen S; Watts NB; Kendler D; Eriksen EF; Mesenbrink PG; Eastell R;
    J Bone Miner Res; 2009 Sep; 24(9):1544-51. PubMed ID: 19338427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Annual intravenous zoledronic acid for three years increased cancellous bone matrix mineralization beyond normal values in the HORIZON biopsy cohort.
    Misof BM; Roschger P; Gabriel D; Paschalis EP; Eriksen EF; Recker RR; Gasser JA; Klaushofer K
    J Bone Miner Res; 2013 Mar; 28(3):442-8. PubMed ID: 23044788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies.
    Chavassieux PM; Arlot ME; Roux JP; Portero N; Daifotis A; Yates AJ; Hamdy NA; Malice MP; Freedholm D; Meunier PJ
    J Bone Miner Res; 2000 Apr; 15(4):754-62. PubMed ID: 10780867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure.
    Jiang Y; Zhao JJ; Mitlak BH; Wang O; Genant HK; Eriksen EF
    J Bone Miner Res; 2003 Nov; 18(11):1932-41. PubMed ID: 14606504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.
    Tanaka M; Mori H; Kayasuga R; Ochi Y; Kawada N; Yamada H; Kishikawa K
    Bone; 2008 Nov; 43(5):894-900. PubMed ID: 18687415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
    Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
    Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
    Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover.
    Borah B; Ritman EL; Dufresne TE; Jorgensen SM; Liu S; Sacha J; Phipps RJ; Turner RT
    Bone; 2005 Jul; 37(1):1-9. PubMed ID: 15894527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.
    Chavassieux PM; Arlot ME; Reda C; Wei L; Yates AJ; Meunier PJ
    J Clin Invest; 1997 Sep; 100(6):1475-80. PubMed ID: 9294113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study.
    Chapurlat RD; Arlot M; Burt-Pichat B; Chavassieux P; Roux JP; Portero-Muzy N; Delmas PD
    J Bone Miner Res; 2007 Oct; 22(10):1502-9. PubMed ID: 17824840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bone histology in postmenopausal osteoporosis--variations in cellular activity].
    Lozo P; Krpan D; Krvavica A; Vukelić Baturić T; Fistonić I; Kusec V
    Acta Med Croatica; 2004; 58(1):5-11. PubMed ID: 15125387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.